FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

José Luis González-Larriba

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
J Zugazagoitia; José Luis González-Larriba; S Hernández; A Manzano; P Pérez; J Puente; J Sanz; M Sotelo; E Díaz-Rubio
Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice.
Joaquim Bellmunt; G Aguilar; J Albanell; Joan Carles; Daniel Castellano; E Gallardo; José Luis González-Larriba; Pablo Maroto; Begoña Mellado; J L Perez-Gracia; C Prior; X Villanueva; A Calvo
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Daniel Castellano; Emilio Esteban; José Luis González-Larriba; Enrique Grande; Luis M Antón-Aparicio; Javier Cassinello; Juan Sepúlveda
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of José Luis González-Larriba (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: J Zugazagoitia; José Luis González-Larriba; S Hernández; A Manzano; P Pérez; J Puente; J Sanz; M Sotelo; E Díaz-Rubio
Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice.
Oncology 2013;84(5):255-64.
2011: Joaquim Bellmunt; G Aguilar; J Albanell; Joan Carles; Daniel Castellano; E Gallardo; José Luis González-Larriba; Pablo Maroto; Begoña Mellado; J L Perez-Gracia; C Prior; X Villanueva; A Calvo
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2646-53.
2011: Daniel Castellano; Emilio Esteban; José Luis González-Larriba; Enrique Grande; Luis M Antón-Aparicio; Javier Cassinello; Juan Sepúlveda
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Expert opinion on pharmacotherapy 2011;12(16):2433-9.
2011: José Ángel Arranz; Miguel Ángel Climent; José Luis González-Larriba; Luis León; José Pablo Maroto
Sorafenib in renal cell carcinoma.
Critical reviews in oncology/hematology 2011;80(2):314-22.
2011: Vega Iranzo; Eloisa Jantus Lewintre; Bartomeu Massuti; Mariano Provencio; Rafael Rossell; Elena Sanmartín; Rafael Sirera; Amalia Velasco; Alfredo Carrato; Mireia Gil; Lorenzo Gómez-Aldaraví; José Luis González-Larriba; Ricardo Guijarro; Ana Blasco; Andrea Cabrera; Carlos Camps
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(6):411-8.
2010: Emiliano Calvo; Pablo Maroto; Xavier García Del Muro; Miguel Angel Climent; José Luis González-Larriba; Emilio Esteban; Rafael López; Luis Paz-Ares; Joaquim Bellmunt; Daniel Castellano
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
Cancer metastasis reviews 2010;29 Suppl 1():1-10.
2010: Emiliano Calvo; Pablo Maroto; Xavier García Del Muro; Miguel Angel Climent; José Luis González-Larriba; Emilio Esteban; Rafael López; Luis Paz-Ares; Joaquim Bellmunt; Daniel Castellano
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
Cancer metastasis reviews 2010;29 Suppl 1():11-20.
2010: Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti
Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3138-45.
2009: Ana Belén Custodio; José Luis González-Larriba; Jana Bobokova; Antonio Calles; Rafael Alvarez; Eugenio Cuadrado; Aranzazu Manzano; Eduardo Díaz-Rubio
Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(7):891-910.
2009: Joaquim Bellmunt; Emiliano Calvo; Daniel Castellano; Miguel Angel Climent; Emilio Esteban; Xavier García del Muro; José Luis González-Larriba; Pablo Maroto; José Manuel Trigo
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Cancer chemotherapy and pharmacology 2009;63 Suppl 1():S1-13.
2007: Joan Carles; Albert Font; Begoña Mellado; Montserrat Domenech; E Gallardo; José Luis González-Larriba; G Catalan; J Alfaro; A Gonzalez Del Alba; Miquel Nogué; P Lianes; J M Tello
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
British journal of cancer 2007;97(9):1206-10.
2007: Pilar Garrido; José Luis González-Larriba; Amelia Insa; Mariano Provencio; Antonio Torres; Dolores Isla; Jose Miguel Sanchez; Felipe Cardenal; Manuel Domine; Jose Ramon Barcelo; Vicente Tarrazona; Andres Varela; Rafael Aguilo; Julio Astudillo; Ignacio Muguruza; Angel Artal; Florentino Hernando-Trancho; Bartomeu Massuti; Maria Sanchez-Ronco; Rafael Rosell
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4736-42.
2007: Joaquim Bellmunt; José Luis González-Larriba; Miguel Angel Climent; Guillermo López-Vivanco; L Urruticoechea; Joan Albanell
Sorafenib TARGET trial results in Spanish patients.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(10):671-3.
2006: Teresa Sampedro Gimeno; Fernando Moreno Antón; Sara López-Tarruella Cobo; José Luis González-Larriba; Vicente Furio Bacete; Eduardo Díaz-Rubio García
Breast metastases as the first sign of recurrence of a cutaneous melanoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(1):57-9.
2003: Vicente Alberola; Carlos Camps; Mariano Provencio; Dolores Isla; Rafael Rosell; Catalina Vadell; Isabel Bover; A Ruiz-Casado; P Azagra; U Jiménez; José Luis González-Larriba; Pilar Diz; Felipe Cardenal; Angel Artal; Alfredo Carrato; S Morales; Jose Javier Sanchez; Ramon de las Peñas; Enriqueta Felip; Guillermo López-Vivanco
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3207-13.
2002: Joaquim Bellmunt; Joan Albanell; Luis Paz-Ares; Miguel Angel Climent; José Luis González-Larriba; Joan Carles; Juan J de la Cruz; Vicente Guillem; Eduardo Díaz-Rubio; Hernán Cortés-Funes; José Baselga
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Cancer 2002;95(4):751-7.
2001: José Luis González-Larriba
[Assessment of mediastinal involvement in lung cancer. Indications of mediastinoscopy, transbronchial puncture, and imaging techniques].
Revista clínica española 2001;201(9):518-21.
2001: Dolores Isla; Rafael Rosell; José Javier Sánchez; Alfredo Carrato; Enriqueta Felip; Carlos Camps; Angel Artal; José Luis González-Larriba; P Azagra; Vicente Alberola; C Martin; Bartomeu Massutí
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1071-7.
2001: José Luis González-Larriba
[Heart diseases caused by cytostatic agents].
Revista clínica española 2001;201(2):90-2.
2000: José Luis González-Larriba; S Serrano; M Alvarez-Mon; F Camacho; Miguel Angel Casado; J L Díaz-Pérez; E Díaz-Rubio; Leslie Fosbrook; Vicente Guillem; J J López-López; J A Moreno-Nogueira; J Toribio
Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2344-52.
2000: Joaquim Bellmunt; Vicente Guillem; Luis Paz-Ares; José Luis González-Larriba; Joan Carles; Eduard Batiste-Alentorn; Alberto Sáenz; Marta López-Brea; Albert Font; Miquel Nogué; R Bastús; Miguel Angel Climent; Juan J de la Cruz; Joan Albanell; J M Banús; E Gallardo; Eduardo Diaz-Rubio; Hernán Cortés-Funes; José Baselga
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3247-55.
2000: J L Senovilla Pérez; Luis Resel Estévez; Jesús Moreno Sierra; Cristina Fernández Pérez; José Luis González-Larriba; Enrique Blanco Jiménez; Angel Silmi Moyano
[Neoadjuvant chemotherapy MVAC in the treatment of infiltrating bladder carcinoma].
Actas urologicas españolas 2000;24(7):536-41.
2000: Joaquim Bellmunt; Vicente Guillem; Luis Paz-Ares; José Luis González-Larriba; Joan Carles; Joan Albanell; Josep Tabernero; Hernán Cortés-Funes; José Baselga
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 2():17-25.
1999: Mariano Monzó; Rafael Rosell; José Javier Sánchez; J S Lee; Aurora O'Brate; José Luis González-Larriba; Vicente Alberola; JC Lorenzo; L Núñez; J Y Ro; C Martín
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1786-93.
1999: Felipe Cardenal; MP López-Cabrerizo; Antonio Antón; Vicente Alberola; Bartomeu Massuti; Alfredo Carrato; Isidoro Barneto; Maria Lomas; Margarita García; P Lianes; Joaquin Montalar; Catalina Vadell; José Luis González-Larriba; B Nguyen; Angel Artal; Rafael Rosell
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):12-8.
1998: Antonio Antón; N Díaz-Fernández; José Luis González-Larriba; Catalina Vadell; Bartomeu Masutti; Joaquin Montalar; Isidoro Barneto; Angel Artal; Rafael Rosell
Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
Lung cancer (Amsterdam, Netherlands) 1998;22(2):139-48.
1998: Enriqueta Felip; Bartomeu Massuti; Carlos Camps; D Benito; Dolores Isla; José Luis González-Larriba; MP López-Cabrerizo; Oscar Salamanca; J Puerto-Pica; Alfredo Moyano; José Baselga; Rafael Rosell
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2723-8.
1997: José Luis González-Larriba; Iciar Garcia Carbonero; Javier Sastre Valera; Pedro Perez-Segura; Eduardo Diaz-Rubio
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 10):90-7.
1997: Rafael Rosell; Enriqueta Felip; Bartomeu Massuti; José Luis González-Larriba; D Benito; MP López-Cabrerizo; Oscar Salamanca; Carlos Camps; J Puerto-Pica
A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-56-S12-60.
1997: T de Portugal Fernández del Rivero; J V Alvarez Gallego; Javier Sastre Valera; J L Alonso Romero; José Luis González-Larriba
[A metastatic muscle mass as the first manifestation of renal-cell cancer. A case report and review of the literature].
Anales de medicina interna (Madrid, Spain : 1984) 1997;14(4):184-6.
1995: Rafael Rosell; José Luis González-Larriba; Vicente Alberola; F Molina; Mariano Monzó; D Benito; J M Pérez; J M de Anta
Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Seminars in oncology 1995;22(6 Suppl 14):12-8.
1995: Vicente Alberola; Rafael Rosell; José Luis González-Larriba; F Molina; F Ayala; Javier García Conde; D Benito; J M Pérez
Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 3():S49-52.
1994: José Luis González-Larriba; Vicente Alberola; P Lianes; A Panizo; Alfredo Carrato; A Muñoz Quintana; Felipe Cardenal; J M Gracia; Alfredo Moyano; Eduardo Díaz-Rubio
[A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients].
Revista clínica española 1994;194(11):953-9.
1993: Miguel Martín; Eduardo Diaz-Rubio; José Luis González-Larriba; Antonio Casado; Javier Sastre; J M López-Vega; JOSE ALMENAREZ; S Dominguez
Ifosfamide in advanced epidermoid head and neck cancer.
Cancer chemotherapy and pharmacology 1993;31(4):340-2.
1992: G García-Casasola; Antonio Casado; R Cigüenza; José Luis González-Larriba; José L Alvarez-Sala
[Rectal melanoma and von Recklinghausen's disease].
Revista clínica española 1992;190(9):475-6.
1992: Eduardo Díaz-Rubio; J Jimeno; Carlos Camps; E Aranda; Bartomeu Massuti; E Blanco; Antonio Antón; J Lízón; José Luis González-Larriba
Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis.
Cancer investigation 1992;10(4):259-64.
1991: M P Morales; Miguel Martín; Eduardo Díaz-Rubio; José Luis González-Larriba; L Audibert; Antonio Casado; JOSE ALMENAREZ
[Superior vena cava syndrome in microcytic carcinoma of the lung: incidence, treatment response and prognostic importance].
Revista clínica española 1991;189(6):268-71.
1991: José Luis González-Larriba
[Early diagnosis of breast cancer].
Revista clínica española 1991;188(5):252-6.
1990: Eduardo Díaz-Rubio; José Luis González-Larriba; Rafael Rosell; A Abad; Miguel Martín; J J Valerdi; J J Barriga
Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(5):379-80.
1986: B Sangro Gómez-Acebo; E Díaz-Rubio García; M Martín Jiménez; José Luis González-Larriba; C Vila Borrajo
[Treatment of microcytic carcinoma of the lung with vincristine, adriamycin, cyclophosphamide and VP-16].
Revista clínica española 1986;179(6):296-301.
1986: M Martín Jiménez; José Luis González-Larriba; B Sangro; Eduardo Díaz-Rubio
[Antiemetic inefficacy of high intravenous doses of metoclopramide by short-term infusion in vomiting induced by antineoplastic chemotherapy].
Medicina clínica 1986;87(5):215-6.